Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ICUI Stock Summary
Top 10 Correlated ETFs
ICUI
In the News
ICU Medical to Present at the KeyBanc Life Sciences & MedTech Investor Forum
SAN CLEMENTE, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the KeyBanc Life Sciences & MedTech Investor Forum being held virtually March 19-20, 2024. ICU Medical's presentation will be on Wednesday, March 20, 2024 at 11:15 a.m. PT (2:15 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, March 20, 2024.
ICU Medical to Present at the Raymond James 45ᵗʰ Annual Institutional Investors Conference
SAN CLEMENTE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the Raymond James 45th Annual Institutional Investors Conference being held in Orlando, Florida, March 3-6, 2024. ICU Medical's presentation will be on Monday, March 4, 2024 at 4:30 a.m. PT (7:30 a.m. ET). Company management will also be participating in one-on-one meetings on Monday, March 4, 2024.
ICU Medical (ICUI) Q4 Earnings and Revenues Surpass Estimates
ICU Medical (ICUI) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $1.60 per share a year ago.
2 Stocks in Focus as New Analysts Initiate Coverage
The recent surge in analyst coverage for stocks such as ICU Medical (ICUI) and Ardmore Shipping (ASC) indicates the potential for significant price appreciation in the near term.
ICU Medical Announces Time of Fourth Quarter 2023 Earnings Conference Call
SAN CLEMENTE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2023 earnings release and conference call.
ICU Medical: Who Is Coming To The Rescue?
ICU Medical, Inc. has faced disappointment and poor performance due to previous acquisitions and lower-quality business activities. The company's recent acquisition of Smiths Medical Business did not meet sales expectations, leading to a shortfall in earnings. ICU Medical's stock has declined significantly, and its leverage ratios are high, causing concerns amidst sales declines of the business.
ICU Medical, Inc. (ICUI) Q3 2023 Earnings Call Transcript
ICU Medical, Inc. (NASDAQ:ICUI ) Q3 2023 Results Conference Call November 6, 2023 4:30 PM ET Company Participants John Mills - Managing Partner at ICR Vivek Jain - Chief Executive Officer and Chairman Brian Bonnell - Chief Financial Officer Conference Call Participants Larry Solow - CJS Securities Jayson Bedford - Raymond James Operator Good afternoon. And welcome to the ICU Medical Inc. Third Quarter 2023 Earnings Conference Call [Operator Instructions].
ICU Medical Announces Time of Third Quarter 2023 Earnings Conference Call
SAN CLEMENTE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2023 earnings release and conference call.
ICU Medical's (ICUI) Plum Duo With Safety Shield Gets 510(k) Nod
The Plum Duo infusion pump represents the latest addition to ICU Medical's (ICUI) advanced lineup of infusion devices.
ICU Medical: Continued Disappointments
ICU Medical's deal with Smiths Medical is underperforming, following a previous troubled deal with Hospira Infusion Systems. Shares have fallen by 50% over the past two years, as the company's outlook is uncertain. The business is facing quality issues and higher interest costs, and its leverage is still high.
ICUI Financial details
ICUI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 61.38 | 60.79 | 62.07 | 95.53 | 93.76 | |
Net income per share | 4.9 | 4.16 | 4.86 | -3.11 | -1.23 | |
Operating cash flow per share | 4.94 | 10.65 | 12.62 | -2.6 | 6.9 | |
Free cash flow per share | -0.2 | 5.85 | 8.79 | -6.76 | 3.01 | |
Cash per share | 14.19 | 19.65 | 26.75 | 8.92 | 10.57 | |
Book value per share | 66.76 | 71.85 | 76.21 | 87.56 | 88.14 | |
Tangible book value per share | 55 | 60.84 | 65.28 | -14.33 | -9.12 | |
Share holders equity per share | 66.76 | 71.85 | 76.21 | 87.56 | 88.14 | |
Interest debt per share | 1.78 | 2.58 | 2.16 | 72.05 | 74.1 | |
Market cap | 3.86B | 4.48B | 5.03B | 3.76B | 2.4B | |
Enterprise value | 3.63B | 4.14B | 4.53B | 5.2B | 3.85B | |
P/E ratio | 38.21 | 51.62 | 48.8 | -50.6 | -81.03 | |
Price to sales ratio | 3.05 | 3.53 | 3.82 | 1.65 | 1.06 | |
POCF ratio | 37.87 | 20.13 | 18.81 | -60.5 | 14.46 | |
PFCF ratio | -936.46 | 36.65 | 27.01 | -23.28 | 33.13 | |
P/B Ratio | 2.8 | 2.99 | 3.11 | 1.8 | 1.13 | |
PTB ratio | 2.8 | 2.99 | 3.11 | 1.8 | 1.13 | |
EV to sales | 2.87 | 3.26 | 3.44 | 2.28 | 1.71 | |
Enterprise value over EBITDA | 24.44 | 30.3 | 31.85 | 22.98 | 13.27 | |
EV to operating cash flow | 35.59 | 18.59 | 16.91 | -83.75 | 23.18 | |
EV to free cash flow | -880.08 | 33.84 | 24.28 | -32.23 | 53.13 | |
Earnings yield | 0.03 | 0.02 | 0.02 | -0.02 | -0.01 | |
Free cash flow yield | 0 | 0.03 | 0.04 | -0.04 | 0.03 | |
Debt to equity | 0.03 | 0.03 | 0.03 | 0.79 | 0.78 | |
Debt to assets | 0.02 | 0.03 | 0.02 | 0.37 | 0.38 | |
Net debt to EBITDA | -1.57 | -2.52 | -3.57 | 6.38 | 5 | |
Current ratio | 3.55 | 4.71 | 5.13 | 2.5 | 2.53 | |
Interest coverage | 115.15 | 23.85 | 61.05 | -0.13 | 0.29 | |
Income quality | 1.01 | 2.56 | 2.59 | 0.84 | -5.6 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0.01 | -0.15 | -0.32 | |
Sales general and administrative to revenue | 0.22 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.04 | 0.03 | 0.04 | 0.04 | 0.04 | |
Intangibles to total assets | 0.14 | 0.13 | 0.12 | 0.54 | 0.54 | |
Capex to operating cash flow | -1.04 | -0.45 | -0.3 | 1.6 | -0.56 | |
Capex to revenue | -0.08 | -0.08 | -0.06 | -0.04 | -0.04 | |
Capex to depreciation | -1.24 | -1.06 | -0.9 | -0.42 | -0.37 | |
Stock based compensation to revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Graham number | 85.77 | 81.96 | 91.32 | 78.31 | 49.41 | |
ROIC | 0.04 | 0.02 | 0.03 | 0 | 0 | |
Return on tangible assets | 0.07 | 0.06 | 0.06 | -0.04 | -0.01 | |
Graham Net | 14.44 | 19.13 | 24.86 | -71.16 | -63.19 | |
Working capital | 633.73M | 725.29M | 829.03M | 740.64M | 737.77M | |
Tangible asset value | 1.13B | 1.27B | 1.38B | -342.1M | -219.62M | |
Net current asset value | 567.06M | 659.35M | 765.1M | -1.19B | -1.04B | |
Invested capital | 0.03 | 0.03 | 0.03 | 0.79 | 0.78 | |
Average receivables | 199.33M | 163.16M | 114.99M | 163.81M | 193.02M | |
Average payables | 124.55M | 100.25M | 76.5M | 148.52M | 182.97M | |
Average inventory | 324.4M | 326.28M | 302.58M | 493.12M | 702.68M | |
Days sales outstanding | 58.29 | 35.64 | 29.36 | 35.49 | 26.55 | |
Days payables outstanding | 59.1 | 32.4 | 35.9 | 49.81 | 35.35 | |
Days of inventory on hand | 155.15 | 142 | 128.44 | 160.56 | 167.15 | |
Receivables turnover | 6.26 | 10.24 | 12.43 | 10.28 | 13.75 | |
Payables turnover | 6.18 | 11.26 | 10.17 | 7.33 | 10.32 | |
Inventory turnover | 2.35 | 2.57 | 2.84 | 2.27 | 2.18 | |
ROE | 0.07 | 0.06 | 0.06 | -0.04 | -0.01 | |
Capex per share | -5.14 | -4.8 | -3.83 | -4.16 | -3.89 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 24.1 | 23.76 | 22.82 | 22.93 | 24.36 | |
Net income per share | -0.65 | -0.41 | -0.41 | 0.3 | -0.71 | |
Operating cash flow per share | -0.07 | 1.72 | -0.06 | 1.46 | 3.78 | |
Free cash flow per share | -1.07 | 1.02 | -0.91 | 0.44 | 2.46 | |
Cash per share | 8.88 | 9.37 | 8.21 | 8.25 | 10.55 | |
Book value per share | 87.12 | 87.77 | 87.84 | 86.95 | 87.96 | |
Tangible book value per share | -14.26 | -13.37 | -11.61 | -9.84 | -9.1 | |
Share holders equity per share | 87.12 | 87.77 | 87.84 | 86.95 | 87.96 | |
Interest debt per share | 69.76 | 69.77 | 69.17 | 68.75 | 69.71 | |
Market cap | 3.78B | 3.95B | 4.29B | 2.87B | 2.41B | |
Enterprise value | 5.22B | 5.37B | 5.74B | 4.31B | 3.86B | |
P/E ratio | -60.79 | -100.59 | -107.96 | 99.2 | -35.1 | |
Price to sales ratio | 6.54 | 6.94 | 7.81 | 5.19 | 4.09 | |
POCF ratio | -2.21K | 95.72 | -2.91K | 81.68 | 26.38 | |
PFCF ratio | -146.62 | 161.08 | -196.09 | 270.86 | 40.6 | |
P/B Ratio | 1.81 | 1.88 | 2.03 | 1.37 | 1.13 | |
PTB ratio | 1.81 | 1.88 | 2.03 | 1.37 | 1.13 | |
EV to sales | 9.03 | 9.45 | 10.44 | 7.79 | 6.56 | |
Enterprise value over EBITDA | 704.37 | 71.48 | 76.34 | 62.67 | 101.71 | |
EV to operating cash flow | -3.05K | 130.3 | -3.89K | 122.57 | 42.27 | |
EV to free cash flow | -202.69 | 219.28 | -262.15 | 406.46 | 65.07 | |
Earnings yield | 0 | 0 | 0 | 0 | -0.01 | |
Free cash flow yield | -0.01 | 0.01 | -0.01 | 0 | 0.02 | |
Debt to equity | 0.79 | 0.78 | 0.78 | 0.78 | 0.78 | |
Debt to assets | 0.37 | 0.37 | 0.37 | 0.37 | 0.38 | |
Net debt to EBITDA | 194.84 | 18.97 | 19.24 | 20.91 | 38.24 | |
Current ratio | 2.5 | 2.62 | 2.57 | 2.63 | 2.53 | |
Interest coverage | -2.46 | 0.86 | 0.11 | 0.95 | -0.58 | |
Income quality | 0.11 | -4.2 | 0.15 | 4.86 | -5.32 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.7 | -0.86 | -0.18 | 0.18 | -0.67 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.04 | 0.03 | 0.04 | 0.04 | 0.04 | |
Intangibles to total assets | 0.54 | 0.54 | 0.54 | 0.53 | 0.54 | |
Capex to operating cash flow | 14.06 | -0.41 | 13.84 | -0.7 | -0.35 | |
Capex to revenue | -0.04 | -0.03 | -0.04 | -0.04 | -0.05 | |
Capex to depreciation | -0.42 | -0.3 | -0.35 | -0.42 | -0.56 | |
Stock based compensation to revenue | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | |
Graham number | 35.63 | 28.45 | 28.56 | 24.22 | 37.49 | |
ROIC | -0.01 | 0 | 0 | -0.01 | 0 | |
Return on tangible assets | -0.01 | 0 | 0 | 0 | -0.01 | |
Graham Net | -70.8 | -69.68 | -68.17 | -65.4 | -63.07 | |
Working capital | 740.64M | 750.85M | 760.86M | 755.37M | 737.77M | |
Tangible asset value | -342.1M | -320.01M | -279.49M | -237.38M | -219.62M | |
Net current asset value | -1.19B | -1.16B | -1.1B | -1.06B | -1.04B | |
Invested capital | 0.79 | 0.78 | 0.78 | 0.78 | 0.78 | |
Average receivables | 219.97M | 180.59M | 150.84M | 162.01M | 163.06M | |
Average payables | 210.47M | 201.16M | 176.74M | 158.17M | 149.66M | |
Average inventory | 660.64M | 721.99M | 761.62M | 767.45M | 734.49M | |
Days sales outstanding | 34.52 | 22.07 | 26.58 | 26.32 | 25.15 | |
Days payables outstanding | 48.21 | 44.55 | 42.12 | 36.37 | 31.39 | |
Days of inventory on hand | 155.41 | 178.75 | 195.46 | 185.08 | 148.41 | |
Receivables turnover | 2.61 | 4.08 | 3.39 | 3.42 | 3.58 | |
Payables turnover | 1.87 | 2.02 | 2.14 | 2.47 | 2.87 | |
Inventory turnover | 0.58 | 0.5 | 0.46 | 0.49 | 0.61 | |
ROE | -0.01 | 0 | 0 | 0 | -0.01 | |
Capex per share | -1 | -0.7 | -0.85 | -1.02 | -1.32 |
ICUI Frequently Asked Questions
What is ICU Medical, Inc. stock symbol ?
ICU Medical, Inc. is a US stock , located in San clemente of Ca and trading under the symbol ICUI
Is ICU Medical, Inc. buy or a sell ?
3 stock analysts have 3 predictions with a medium analyst target price of $211. The lowest prediction is $190 and the highest is $235
What is ICUI stock prediction ?
What is ICU Medical, Inc. stock quote today ?
ICU Medical, Inc. stock price is $102.89 today.
Is ICU Medical, Inc. stock public?
Yes, ICU Medical, Inc. is a publicly traded company.